FGFR2

Cogent Biosciences Announces Annual Meeting of Stockholders

Retrieved on: 
Thursday, June 2, 2022
SEC filing, LinkedIn, Notice, HER2/neu, Investor, KIT, Annual general meeting, Nasdaq, FGFR2, GLOBE, Patient, Social media, Twitter, SEC, B cell, GIST, Shareholder, Mutation, Pharmaceutical industry

and BOULDER, Colo., June 02, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the Annual Meeting of Stockholders will take place virtually on June 7, 2022 at 9:00am ET.

Key Points: 
  • and BOULDER, Colo., June 02, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the Annual Meeting of Stockholders will take place virtually on June 7, 2022 at 9:00am ET.
  • All relevant documents and information relating to the annual meeting, including the notice and agenda, are available in the Investors and Media section of Cogents website under SEC Filings/DEF 14A Proxy.
  • Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases.
  • Cogent Biosciences is based inCambridge, MAandBoulder, CO.Visit our website for more information at www.cogentbio.com.

Global Urothelial Carcinoma Pipeline Market Report 2022: Therapeutics Assessment for 50+ Pipeline Drugs by Product Type, Stage, Route of Administration, and Molecule Type - ResearchAndMarkets.com

Retrieved on: 
Monday, May 30, 2022
Pharmaceutical, Health, Oncology, MMAE, Immunotherapy, HER2, Carcinoma, II, Achondroplasia, FGFR3, New Drug Application, News, Patient, Trastuzumab, ADC, ALK5, Therapy, Clinical trial, Marketing, GEJ, Metastasis, FGFR2, Technology, NMPA, NDA, Pre-registration house officer, Discovery, Acquisition, QED, Pharmaceutical industry, Vaccine, Squamous cell carcinoma

This "Urothelial Carcinoma- Pipeline Insight, 2022" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Urothelial Carcinoma pipeline landscape.

Key Points: 
  • This "Urothelial Carcinoma- Pipeline Insight, 2022" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Urothelial Carcinoma pipeline landscape.
  • It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
  • A detailed picture of the Urothelial Carcinoma pipeline landscape is provided which includes the disease overview and Urothelial Carcinoma treatment guidelines.
  • The assessment part of the report embraces, in depth Urothelial Carcinoma commercial assessment and clinical assessment of the pipeline products under development.

Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022

Retrieved on: 
Thursday, May 26, 2022
Cancer, Physician, Part, UC, Company, Annual general meeting, NRAS, FIH, U.S. Securities and Exchange Commission, FGFR3, Nasdaq, KNTE, Patient, MBBS, Mass, Squamous cell carcinoma, Abstract (summary), Pharmacokinetics, Clinical trial, Society, COVID-19, Adult, Binimetinib, Research, SAN, Intention, Industry, FGFR2, MAPK, Cholangiocarcinoma, Safety, ASCO, Risk, Therapy, Security (finance), LinkedIn, ICC, SEC, Growth, MD, GLOBE, Pharmaceutical industry, FGFR

SAN FRANCISCO and SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc .

Key Points: 
  • SAN FRANCISCO and SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc .
  • We are pleased to share additional details of this two-part Phase 1 trial-in-progress evaluating KIN-3248 at this years ASCO conference.
  • A Phase 1/1b dose escalation and expansion clinical trial evaluating the safety and efficacy of KIN-2787 is ongoing ( NCT04913285 ).
  • Kinnate will also host an exhibit at the 2022 ASCO Annual Meeting at booth number 3047.

Helsinn Establishes New R&D Hub in the U.S. to Support its Global Fully Integrated Targeted Therapy (FITT) Strategy

Retrieved on: 
Wednesday, May 25, 2022
Chemistry, Cancer, FITT, Â, Environment, Respect, Patient, CMC, GPX4, CCA, FGFR2, FGFR, HTU, Vomiting, Heart, RET, Therapy, Corporation, Transfection, Growth, Fine chemical, Pharmaceutical industry

Bringing this R&D expertise into HTU through this new hub complements the global R&D organization and is the next step in Helsinns strategy of creating a differentiated pipeline of highly innovative oncology assets and transforming Helsinn from a leading cancer supportive care company to a Fully Integrated Targeted Therapy company.

Key Points: 
  • Bringing this R&D expertise into HTU through this new hub complements the global R&D organization and is the next step in Helsinns strategy of creating a differentiated pipeline of highly innovative oncology assets and transforming Helsinn from a leading cancer supportive care company to a Fully Integrated Targeted Therapy company.
  • Over the next five years, Helsinn intends to continue investing approximately 35 percent of the revenues from its commercial engine of supportive care and cancer therapeutic products into targeted therapeutics R&D.
  • Dr. Giorgio Calderari, Helsinn Group CEO & Board Member, said: The implementation of Helsinns strategy continues at pace and we are excited to announce the enlarging of our global R&D organization by establishing a new hub in the U.S. as part of HTU.
  • Helsinn is a fully integrated, global biopharma company headquartered in Lugano, Switzerland.

Innovent Will Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Monday, May 16, 2022
Efficacy, Control, NDA, Safety, Ophthalmology, Cancer, Eli Lilly and Company, Medicine, KRAS, News, Nature, Integrity, Marketing, American Society of Clinical Oncology, NSCLC, CMC, SAN, Housing and Building National Research Center, Social conditions in Honduras, Motherboard, Company, Autoimmunity, Sintilimab, Patient, Ruijin Hospital, FGFR2, Shanghai Jiao Tong University School of Medicine, ASCO, Eli Lilly, HKEX, MD Anderson Cancer Center, Translational medicine, TKI, TIK, Environment, PI3K, Bevacizumab, Society, Chemistry, BCL, Stock exchange, NMPA, State Key Laboratories, Pharmaceutical industry, Medical device, Generic drug, Spotlight Innovation, Incyte, Ramucirumab, Hematology

Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic, ophthalmologyand other major diseases.

Key Points: 
  • Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic, ophthalmologyand other major diseases.
  • On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
  • Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
  • Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.

Kinnate Biopharma Inc. Reports First Quarter 2022 Financial Results and Provides Operational Updates

Retrieved on: 
Thursday, May 12, 2022
UC, NRAS, Research, U.S. Securities and Exchange Commission, Pharmacokinetics, MEK, Risk, American Association, SEC, Cancer, Annual general meeting, KNTE, Investment, Squamous cell carcinoma, Clinical trial, COVID-19, SAN, State Administrative Expenses, Growth, GLOBE, FGFR3, American Society of Clinical Oncology, Association, BRAF, Adult, FGFR2, Cholangiocarcinoma, ASCO, Therapy, Corporation, Administration, ICC, Security (finance), FIH, Nasdaq, Patient, View, AACR, Society, Binimetinib, Industry, Safety, Development, Melanoma, Pharmaceutical industry, Cryptocurrency, FGFR

SAN FRANCISCO and SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced financial results for the quarter ended March 31, 2022.

Key Points: 
  • (Nasdaq: KNTE) (Kinnate), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced financial results for the quarter ended March 31, 2022.
  • Our consistent, disciplined use of capital and updated cash runway guidance is expected to enable Kinnate to fund scientific innovation and operations into early 2024.
  • Recent Business Highlights and Corporate Update:
    Initial monotherapy data from the ongoing Phase 1 KN-8701 clinical trial expected in the fourth quarter of 2022.
  • Net Loss: First quarter net loss for 2022 was $26.9 million, compared to $17.5 million for the same period in 2021.

Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress

Retrieved on: 
Thursday, May 12, 2022
Social media, Nasdaq, Apex, Method, Patient, European Hematology Association, Poster, KIT, HER2/neu, GIST, EHA, FGFR2, Congress, B cell, LinkedIn, Mutation, Twitter, Novel, GLOBE, Pharmaceutical industry

and BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced a poster presentation at the European Hematology Association (EHA) Congress being held June 9-12, 2022.

Key Points: 
  • and BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced a poster presentation at the European Hematology Association (EHA) Congress being held June 9-12, 2022.
  • The poster will review initial clinical data from the Companys ongoing Phase 2 APEX trial with bezuclastinib.
  • The abstract is available on the EHA website at www.ehaweb.org and the poster will be published on the EHA Congress platform on June 10, 2022.
  • Cogent Biosciences is based inCambridge, MAandBoulder, CO.Visit our website for more information at www.cogentbio.com .

LianBio Reports First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 12, 2022
National Medical Products Administration, Company, BMS, American College, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Research, Cardiology, SRT, U.S. Securities and Exchange Commission, Director, New Drug Application, NBTXR3, Patient, Inflammation, Clinical trial, Pfizer, Adult, Bristol Myers Squibb, FDA, Center for Drug Evaluation and Research, Oxford Handbook of Clinical Medicine, CCA, U.S. FDA, CDE, FGFR2, Biotechnology, FGFR, Center, Forward-looking statement, Board, Cisplatin, NMPA, Safety, Therapy, Respiratory syncytial virus, Gene amplification, Coronavirus Scientific Advisory Board (Turkey), Ophthalmology, SEC, Acquisition, DB, SAB, GLOBE, Pharmaceutical industry, Medicine, Medical imaging, Fine chemical

SHANGHAI, China and PRINCETON, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Key Points: 
  • SHANGHAI, China and PRINCETON, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
  • In January 2022, LianBio initiated the Phase 3 EXPLORER-CN clinical trial of mavacamten in Chinese patients with symptomatic oHCM.
  • In May 2022, LianBio announced topline results from the Phase 1 pharmacokinetic (PK) study of mavacamten in healthy Chinese volunteers.
  • Research and development expenses were $12.3 million for the first quarter of 2022 compared to $53.4 million for the first quarter of 2021.

Helsinn to present data at upcoming AMMF’s 2022 European Cholangiocarcinoma Conference

Retrieved on: 
Wednesday, May 11, 2022
CCA, Cholangiocarcinoma, Cancer, Bile, Radisson Blu Hotel Hamburg, Patient, FITT, Doctor of Philosophy, Alan, FGFR, Caregiver, Diagnosis, Environment, Incidence, Respect, MD, Corporation, AMMF, Observational study, London Stansted Airport, Master of Science, Research, Heart, Growth, Awareness, FGFR2, Pharmaceutical industry, Medical imaging

Helsinn will be present with a tabletop exhibit and will also contribute to the scientific exchange through the presentation of two scientific posters.

Key Points: 
  • Helsinn will be present with a tabletop exhibit and will also contribute to the scientific exchange through the presentation of two scientific posters.
  • AMMFs 2022 cholangiocarcinoma (CCA) conference will mark 20 years since the inception of AMMF UK Cholangiocarcinoma Charity.
  • The first poster is entitled Natural history of patients with advanced cholangiocarcinoma and FGFR2 gene fusions/rearrangements.
  • Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results

Retrieved on: 
Tuesday, May 10, 2022
D, Forward-looking statement, Mutation, Private Securities Litigation Reform Act, EHA, IND, Nasdaq, Twitter, GLOBE, European Hematology Association, APEX, Pleural effusion, Safety, Research, Patient, Stromal cell, B cell, American Association, Risk, Mastocytosis, Annual report, American Association for Cancer Research, GIST, LinkedIn, PDGFR, Investigational New Drug, Congress, Cash, SEC, AACR, CEO, HER2/neu, Toxic epidermal necrolysis, Growth, FLT3, KIT, Edema, Social media, FGFR2, Pharmaceutical industry, PEAK, CSF1R, Cogent

CAMBRIDGE, Mass. and BOULDER, Colo., May 10, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced financial results for the first quarter ended March 31, 2022.

Key Points: 
  • and BOULDER, Colo., May 10, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced financial results for the first quarter endedMarch 31, 2022.
  • We continue to make significant progress towards our strategic priorities for 2022, said Andrew Robbins, President and CEO of Cogent Biosciences.
  • R&D Expenses: Research and development expenses were $25.5 million for the first quarter of 2022 compared to $8.2 million for the first quarter of 2021.
  • G&A Expenses:General and administrative expenses were $5.9 million for the first quarter of 2022 compared to $4.6 million for the first quarter of 2021.